InterventionsHuman trial

Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial

Figure 1 from Diabetes Therapy — Figure 1Stewart et al.

Diabetes Therapy

The paper

Katie D. Stewart, Louis S. Matza, Chanadda Chinthammit,

Imre Pavo, Amy K. Bartee,

Kristina Secnik Boye

Thermo Fisher Scientific (United States) · Eli Lilly (United States)

Diabetes Therapy · 17 Sep 2026

doi.org/10.1007/s13300-026-01907-y PubMed 42754765

Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026